Gene:
ADAM17
ADAM metallopeptidase domain 17

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  TACE
Alternate Symbols:  CD156B; cSVP
PharmGKB Accession Id: PA24512

Details

Cytogenetic Location: chr2 : p25.1 - p25.1
GP mRNA Boundary: chr2 : 9629392 - 9695917
GP Gene Boundary: chr2 : 9626392 - 9705917
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to ADAM17: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. Pharmacogenetics and genomics. 2010. Potter Catherine, et al. PubMed

LinkOuts

Entrez Gene:
6868
OMIM:
603639
UCSC Genome Browser:
NM_003183
RefSeq RNA:
NM_003183
RefSeq Protein:
NP_003174
RefSeq DNA:
AC_000045
AC_000134
NC_000002
NT_005334
NW_001838766
NW_927719
UniProtKB:
B2RNB2_HUMAN (B2RNB2)
ADA17_HUMAN (P78536)
Ensembl:
ENSG00000151694
GenAtlas:
ADAM17
GeneCard:
ADAM17
MutDB:
ADAM17
ALFRED:
LO001129N
HuGE:
ADAM17
Comparative Toxicogenomics Database:
6868
ModBase:
P78536
HumanCyc Gene:
HS07763
HGNC:
195

Common Searches